Skip to content

Development Pipeline

Page 'Sub' Navigation:

Page Path 'Breadcrumb':

HIV

HIV Market Opportunity Overview

 
  • Worldwide, an estimated 39.5 million people are living with HIV1
  • Between 1.04 and 1.85 million people are living with HIV in the U.S.2
  • An estimated 2.2 million people in Europe are living with HIV3
  • Emergence of drug resistance has thwarted global efforts to effectively manage HIV infection4
  • There is a need for safe and convenient drug combinations to improve patient compliance.
  1. Global AIDS epidemic continues to grow. New data also show HIV prevention programs getting better results if focused on reaching people most at risk and adapted to changing national epidemics. Geneva, Switzerland: World Health Organization; November 21, 2006.
  2. A glance at the HIV/AIDS epidemic. CDC HIV/AIDS Fact Sheet. Atlanta, GA: Centers for Disease Control and Prevention; January 2007.
  3. HIV/AIDS in Europe: overview. Fact Sheet EURO/14/05. Geneva, Switzerland: World Health Organization Europe; November 28, 2005.
  4. Briefing Note-HIV drug resistance. Geneva, Switzerland: World Health Organization. Report from Conference on Retroviruses and Opportunistic Infections; February 25-28, 2007.

RDEA806

 
RDEA806, a non-nucleoside reverse transcriptase inhibitor (NNRTI) for the potential treatment of HIV infection, has successfully completed Phase 1 and Phase 2a studies and has been evaluated in over 250 subjects. Results from a Phase 2a monotherapy proof-of-concept study of RDEA806 demonstrated placebo-adjusted plasma viral load reductions of up to 2.0 log10 on day 8 with once-daily dosing of RDEA806. All dosing regimens tested were well-tolerated in this study.

The timing of future trials of RDEA806 and our other NNRTIs will be determined by the results of our partnering efforts.

RDEA427

 
RDEA427, a next-generation NNRTI, is from a chemical class that is distinct from the RDEA806 chemical class. Based on preclinical results, RDEA427 demonstrates many of the same positive attributes as RDEA806, but is more potent, has superior pharmacokinetic properties, and has even greater activity against a wide range of drug-resistant viral isolates than RDEA806. We have evaluated RDEA427 in a human microdose pharmacokinetic study. Beyond RDEA427 is our 900 Series of NNRTIs; these are chemically distinct from both the RDEA806 and RDEA427 classes of molecules.

The timing of future trials of RDEA427 and our other NNRTIs will be determined by the results of our partnering efforts.